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Cluster randomised trial of intermittent preventive
treatment for malaria in infants in area of high, seasonal
transmission in Ghana
Daniel Chandramohan, Seth Owusu-Agyei, Ilona Carneiro, Timothy Awine,
Kwame Amponsa-Achiano, Nathan Mensah, Shabbar Jaffar, Rita Baiden, Abraham Hodgson,
Fred Binka, Brian Greenwood
Abstract
Objective To evaluate the effects of intermittent
preventive treatment for malaria in infants (IPTi) with
sulfadoxine-pyrimethamine in an area of intense,
seasonal transmission.
Design Cluster randomised placebo controlled trial,
with 96 clusters allocated randomly to
sulfadoxine-pyrimethamine or placebo in blocks of
eight.
Interventions Children received
sulfadoxine-pyrimethamine or placebo and one
month of iron supplementation when they received
DPT-2, DPT-3, or measles vaccinations and at 12
months of age.
Main outcome measures Incidence of malaria and of
anaemia determined through passive case detection.
Results 89% (1103/1242) of children in the placebo
group and 88% (1088/1243) in the IPTi group
completed follow-up to 24 months of age. The
protective efficacy of IPTi against all episodes of
malaria was 24.8% (95% confidence interval 14.3% to
34.0%) up to 15 months of age. IPTi had no
protective effect against malaria between 16 and 24
months of age (protective efficacy –4.9%, − 21.3% to
9.3%). The incidence of high parasite density malaria
( ≥ 5000 parasites/l) was higher in the IPTi group
than in the placebo group between 16 and 24 months
of age (protective efficacy − 19.5%, − 39.8% to
− 2.2%). IPTi reduced hospital admissions with
anaemia by 35.1% (10.5% to 52.9%) up to 15 months
of age. IPTi had no significant effect on anaemia
between 16 and 24 months of age (protective efficacy
− 6.4%, − 76.8% to 35.9%). The relative risk of death
up to 15 months of age in the IPTi group was 1.26
(95% confidence interval 0.81 to 1.96; P = 0.31), and
from 16 to 24 months it was 1.28 (0.77 to 2.14;
P = 0.35).
Conclusions Intermittent preventive treatment for
malaria with sulfadoxine-pyrimethamine can reduce
malaria and anaemia in infants even in seasonal, high
transmission areas, but concern exists about possible
rebound in the incidence of malaria in the second
year of life.
Introduction
Malaria remains the leading cause of morbidity and
mortality in young children in impoverished commu-
nities in Africa. It is estimated that 515 (range 300-600)
million clinical attacks of falciparum malaria occurred
globally in 2002 and that 70% of these cases occurred
in Africa.1 Malaria is one of the major causes of
anaemia in children in sub-Saharan Africa, accounting
for an estimated 18% of the disability adjusted life
years lost because of anaemia.2 The number of deaths
attributable to malaria associated anaemia is estimated
at 190 000 to 974 000 a year.3 In high intensity
transmission areas, the highest burden of malaria and
malaria associated anaemia is in infants.4
Control of malaria and anaemia depends largely
on passive case detection and appropriate treatment.
However, many children who have malaria parasitae-
mia, anaemia, or both remain asymptomatic,5 and
chronic asymptomatic parasitaemia increases the risk
of severe anaemia.6 Chemoprophylaxis during the first
year of life significantly reduced the incidence of
malaria and anaemia in a study in Tanzania.7 The risk
of malaria and anaemia increased in the second year of
life after chemoprophylaxis had been stopped,
however, suggesting that complete protection against
malaria infection during infancy had impaired
naturally acquired immunity against the infection. Two
recent studies in Tanzania, done in areas with perennial
transmission of malaria, showed that administration of
a full therapeutic course of an antimalarial at set times
during infancy, regardless of whether or not the infant
was parasitaemic (intermittent preventive treatment in
infants (IPTi)), substantially reduced the incidence of
malaria and anaemia.8 9 The antimalarial was given in
A figure and three tables are on bmj.com
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association with vaccination in one study and at the
time of growth monitoring visits in the other. Whether
IPTi linked to a child immunisation schedule will have
a similar protective effect in areas with intense,
seasonal transmission is not known. We aimed to
evaluate the effects of IPTi with sulfadoxine-
pyrimethamine in an area of intense, seasonal
transmission in northern Ghana.
Methods
Study site
We did the study in the Kassena-Nankana district in
the Upper East region of Ghana, which lies within the
open woodland, sub-Sahel region of West Africa.
Annual rainfall averages 850 mm, with most rain
falling during June to October. The entomological
inoculation rate was estimated to be 418 infective bites
per person per year in 2001-2, and almost all infective
bites occur between June and November, coinciding
with the rainy season.10 The prevalence of parasitaemia
in 2-12 month old infants at the end of the dry season
in June 2000 was 8.6% (95% confidence interval 6.6%
to 11.0%); this increased to 52.8% (48.7% to 56.7%) at
the end of the rainy season (November 2000). The
prevalence of a packed cell volume < 24% showed a
similar seasonal pattern, increasing from 2.4% (1.4% to
3.9%) in the dry season to 12.6% (10.1% to 15.4%) at
the end of the rainy season (unpublished data from
baseline simple random sample cross sectional
surveys). The 14 day adequate clinical and parasitologi-
cal response rate after treatment with sulfadoxine-
pyrimethamine for clinical malaria (geometric mean
parasite density 18 978/l, range 2000-530 000/l) in
children aged 6-59 months was 77.6% (68.9% to
84.8%) in 2004.11 However, the day 14 parasite
clearance rate in asymptomatic children aged 19-45
months (geometric mean parasite density 2595/l,
range 120-48 640/l) was 94.5% (90.2% to 97.3%)
(unpublished data from drug sensitivity study carried
out in the IPTi study children in 2004, after all children
had completed follow-up at 18 months of age).
A demographic surveillance system for monitoring
vital events has been operating in this district since
1993. The area is divided into four zones, and within
each zone households (compounds) are grouped into
clusters. On average, a cluster has 100 households. The
district contained 244 clusters of households in 2000.
We restricted the study to the central and southern
zones, which had a total of 96 clusters of households.
All infants living in these clusters of households
without a history of allergy to sulfadoxine-
pyrimethamine were eligible for enrolment in the
study. The study area has one hospital with 140 beds
and 11 community health centres that provide
outpatient care only. In addition, there are 18 outreach
clinics where only expanded programme of immunisa-
tion (EPI) and growth monitoring are provided. The
study infants were enrolled in these 30 EPI delivery
points.
Primary objective and sample size
The primary objective was to determine the effect of
IPTi on the incidence of anaemia.We assumed that the
incidence of anaemia would be 25% in the placebo
group and 18.7% in the IPTi group and that the coeffi-
cient of variation between clusters (k) would be 0.1.
With the available 96 clusters, each of 25 children on
average, the study had approximately 95% power to
detect a statistically significant difference in the
incidence of anaemia at the 5% two sided significance
level.
Randomisation and study drugs
We randomly allocated 96 clusters of households to
sulfadoxine-pyrimethamine or placebo in blocks of
eight clusters by using a computer generated list. To
increase blinding, we assigned clusters allocated to
sulfadoxine-pyrimethamine or placebo to eight differ-
ent drug codes (four sulfadoxine-pyrimethamine and
four placebo). A statistician at the London School of
Hygiene and Tropical Medicine generated and kept
safe the randomisation list of clusters and drug codes.
The study team and caretakers of study children were
blinded to the drug codes. Study infants received half a
tablet of sulfadoxine-pyrimethamine or an identical
placebo when they received DPT-2 or DPT-3 vaccines
and one tablet of sulfadoxine-pyrimethamine or
placebo when they received measles vaccine and at 12
months of age, according to the cluster where they
lived. In addition to sulfadoxine-pyrimethamine or
placebo, all infants received one month’s supply of iron
supplement (2.5 ml, 15 mg elemental iron, twice weekly
for four weeks) when they received DPT-2, DPT-3, or
measles vaccines and at 12 months of age.We obtained
sulfadoxine-pyrimethamine and placebo from Cos-
mos Pharmaceuticals, Nairobi. The content and
solubility of the sulfadoxine-pyrimethamine tablets
were confirmed by solubility testing and high perform-
ance liquid chromatography at the London School of
Hygiene and Tropical Medicine. Study drugs were
crushed and mixed with water and administered by a
study field worker at an EPI clinic.
Enrolment and follow-up
Enrolment of study infants started in September 2000,
and follow-up to 24 months of age was completed in
June 2004. The nature of the trial was explained to
caretakers of infants attending the study EPI clinics for
DPT-1 vaccine, and they were invited to enrol their
infant in the study. After informed written consent had
been obtained, infants were enrolled, assigned a
unique personal identity number, and allocated to the
respective study group according to the cluster where
they lived. All study infants were given a photo identity
card, and their guardians were asked to bring the card
whenever they visited an EPI clinic or other health
facility. A field worker visited the households of study
infants one or two days before the date when DPT-2
(IPT-1), DPT-3 (IPT-2), and measles (IPT-3) vaccinations
were due to remind caretakers to attend an EPI clinic.
A similar visit was made shortly before the IPT-4
administration at the age of 12 months was due. Finger
prick blood samples for assessing packed cell volume,
malaria parasitaemia, and the immune response to EPI
vaccines were taken when infants received IPT-1, IPT-3,
and IPT-4. Immune responses to EPI vaccines are
being tested as part of a larger study commissioned by
the IPTi consortium, and these results will be reported
elsewhere.
We used a morbidity questionnaire to assess all
study children who presented with any illness at one of
the 11 health centres or at the hospital outpatient
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department. We collected blood samples for malaria
parasites from all children who had fever or a history
of fever during the previous two days. We used an
inpatient morbidity questionnaire to assess children
who were admitted to the hospital and took blood
samples for microscopy and determination of packed
cell volume.
Study children were visited at home at 18 months
of age to collect finger prick blood samples for assess-
ing packed cell volume and the presence of malaria
parasitaemia and again at 23 months of age to assess
their health. The study physician certified the cause of
death of children who died in the hospital. We assessed
cause of death of children who died at home by verbal
autopsy.12
A fieldworker visited a random 20% sample of
study children at home within four weeks after admin-
istration of IPT dose 1 or dose 2 to assess adherence to
administration of iron at home and to inquire about
adverse events. Children who had any rash other than
scabies, heat rash, or insect bites were referred to the
project physician for a clinical assessment.
Ethical clearance and analytical plan
An independent statistician (Simon Cousens) and epi-
demiologist (Laura Rodrigues) approved the analytical
plan. We cleaned and audited the data before locking
the data and unmasking the intervention codes. The
primary outcomes, defined in the analytical plan, were
the incidence of all episodes of malaria associated
fevers (history of fever or temperature ≥ 37.5°C plus
malaria parasites detected on a blood smear) detected
in study children attending the health centres or the
hospital and the incidence of anaemia (packed cell vol-
ume < 24%) in children admitted to the study hospital
for any illness. We stratified analyses by age (2-15
months and 16-23 months) to assess the effect of IPTi
during the intermittent treatment phase (2-15 months)
and after the effect of the intervention had ceased
(16-23 months). We decided a priori to investigate the
effect of sex, urban residence, and mosquito net use on
the outcome, including only those covariates that were
significantly associated with the outcome (P < 0.1) in
the final model.
Because of the highly seasonal nature of transmis-
sion of malaria at the study site, we compared the effect
of IPTi administered during the wet season (July-
November) with IPTi administered during the dry sea-
son (December-June). We restricted this analysis to
2-12 month old infants. We estimated the protective
efficacy of IPTi against malaria, anaemia, and hospital
admissions by all combinations of timing of IPTi doses.
Statistical methods
We analysed data on an intention to treat basis, includ-
ing all infants who were enrolled, at the time of receipt
of DPT-1, regardless of whether they received any
doses of IPT. Time at risk started at enrolment,
approximately four weeks before the first dose was
administered and will, therefore, give a conservative
estimate of the effect of IPTi. Thirty episodes of malaria
occurred in 127.5 person years at risk in the placebo
group and 30 episodes in 127.1 person years at risk in
the sulfadoxine-pyrimethamine group in the period
between enrolment and the first dose received. We
analysed data by using random effects Poisson or
negative binomial regression models to allow for intra-
cluster correlation at the level of randomisation
(household cluster) and to adjust for important covari-
ates. We used Poisson regression to analyse the
incidence of anaemia, cerebral malaria, hospital admis-
sions, and death.We used negative binomial regression
to analyse the incidence of malaria associated fevers
and high density fevers, as these were significantly clus-
tered within individuals. We calculated person time at
risk from the date of enrolment to second birthday,
date of migration, or date of death. In addition, if a
child had received an antimalarial drug during the
follow-up period, we subtracted the 28 day post-
treatment period from the person time at risk. We ana-
lysed data on cross sectional outcomes by using a
random effects logistic regression model.
Results
Between September 2000 and June 2004, 2485 infants
were enrolled in the study and followed up until the
age of 24 months, death, or migration out of the study
area. The number of children per cluster varied but was
well balanced between the two groups. It ranged from
2 to 47 (mean 30.1) in the IPTi group and from 7 to 47
(mean 29.5) in the placebo group. The proportions of
infants who received drug treatment at different time
points and the proportion of children followed up to
24 months of age were similar between the IPTi and
control groups (see figure on bmj.com). Table A on
bmj.com shows the characteristics of the infants in
each arm of the study. Tables 1 and 2 summarise the
effects of IPTi on malaria, anaemia, and other
outcomes.
Incidence of malaria
The incidence of malaria was significantly lower in the
IPTi group than in the placebo group up to 15 months
of age (table 1). The protective efficacy of IPTi against
all episodes of malaria was 24.8% (95% confidence
interval 14.3% to 34.0%). IPTi had no effect on the
incidence of malaria between 16 and 24 months of age
(protective efficacy − 4.9%, − 21.3% to 9.3%). From 2
to 24 months of age IPTi had a protective efficacy of
16.1% (6.4% to 24.8%) (table 2). Kaplan-Meier survival
analysis of time to first episode of malaria (figure) sug-
gests that much of the protective effect against malaria
occurred after the first and second doses, with some
indication of waning of effect with time (log rank
2 = 16.4, P = 0.0001 for 0-8 months; log rank 2 = 8.86,
P = 0.0029 for 9-15 months, and log rank 2 = 0.14,
P = 0.7093 for 16-24 months). Although the protective
efficacy against all malaria episodes during a one
month post-IPTi period was not significantly different
between the four courses of IPTi, during the second
month after IPTi the protective efficacy of IPTi dose 4
was significantly lower than that seen after dose 2
(table 3).
Protective efficacy of IPTi against malaria attacks
associated with high parasite density (defined a priori
as ≥ 5000 parasite/l) up to 15 months of age was
similar to the protective efficacy against malaria attacks
of any parasite density (23.3%, 10.8% to 34.1%)
(table 2). The incidence of high parasite density
malaria was significantly higher in the IPTi group than
in the placebo group between 16 and 24 months of age
(protective efficacy − 19.5%, − 39.8% to − 2.2%). From
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2 to 24 months of age IPTi had a protective efficacy of
11.5% (0.0% to 21.6%) against high parasite density
malaria.
Incidence of anaemia
The incidence of all episodes of anaemia (packed cell
volume < 24%), identified through passive case detec-
tion, was significantly lower in the IPTi group than in
the placebo group up to 15 months of age (table 1).
The protective efficacy of IPTi against anaemia was
35.1% (10.5% to 52.9%). IPTi had no significant effect
on the incidence of anaemia between 16 and 24
months of age (protective efficacy − 6.4%, − 76.8% to
35.9%). From 2 to 24 months of age IPTi had a protec-
tive efficacy of 23.8% ( − 1.3% to 42.6%) against
anaemia (table 2).
The incidence of anaemia associated with malaria
parasitaemia was also significantly lower in the IPTi
group up to 15 months of age (table 1). The protective
efficacy of IPTi against malaria associated anaemia was
53% (22.8% to 71.3%). The incidence of malaria
associated anaemia increased in the IPTi group by
26.3% ( − 44.9% to 189.8%) between 16 and 24 months
of age, but this difference was not statistically
significant. From 2 to 24 months of age IPTi had a pro-
tective efficacy of 10.5% ( − 1.6% to 19.3%) against
malaria associated anaemia (table 2).
Incidence of severe disease and mortality
The incidence of hospital admissions for all causes was
13.2% ( − 4.5% to 28.0%) lower in the IPTi group than
in the placebo group up to 15 months of age, but this
reduction was not statistically significant (table 2). We
found no significant difference between groups in the
all cause hospital admission rate between 16 and 24
months. The incidence of all cause hospital admissions
from 2 to 24 months of age was slightly lower in the
IPTi group, but this difference was not statistically sig-
nificant (9.5%, − 7.5% to 23.8%).
Table 1 Outcomes in sulfadoxine-pyrimethamine (SP) and placebo arms by age group
Outcomes
2-15 months 16-24 months
Placebo SP Odds ratio
(95% CI)
Placebo SP Odds ratio
(95% CI)Events Rate* Events Rate* Events Rate* Events Rate*
Malaria
Person years at risk – 1325 – 1324 – – 732 – 722 –
All episodes of malaria 1348 1017.0 1009 762.2 0.75 (0.66 to 0.86)† 579 790.8 609 843.9 1.05 (0.91 to 1.21)‡
Malaria (≥5000 parasites/l) 813 613.4 627 473.6 0.76 (0.66 to 0.89) 337 460.3 403 558.4 1.19 (1.02 to 1.39)
Hospital admissions
Person years at risk – 1418 – 1415 – – 763 – 756 –
All causes 457 322.3 403 284.8 0.87 (0.73 to 1.05) 139 182.2 136 179.8 1.0 (0.98 to 1.31)
All malaria admissions 85 60.7 53 37.5 0.60 (0.42 to 0.86) 35 45.9 32 42.3 0.92 (0.54 to 1.56)
PCV<24% 97 68.4 63 44.5 0.65 (0.47 to 0.89)§ 35 45.9 37 48.9 1.09 (0.66 to 1.81)¶
PCV<15% 18 12.7 10 7.1 0.56 (0.26 to 1.21) 7 9.2 4 5.3 0.57 (0.16 to 2.04)
Malaria + PCV<24% 49 34.6 23 16.3 0.47 (0.28 to 0.77) 11 14.4 14 18.5 1.28 (0.56 to 2.95)
Malaria + PCV<15% 8 5.6 5 3.5 0.64 (0.21 to 1.95) 4 5.2 0 0 –
Cerebral malaria 21 14.8 15 10.6 0.68 (0.35 to 1.35) 16 21.0 12 15.9 0.81 (0.33 to 1.99)
Deaths
Person years at risk – 1418 – 1415 – 763 – 756 –
All causes 35 24.6 44 31.1 1.27 (0.82 to 1.99) 26 34.1 33 43.7 1.27 (0.76 to 2.13)
Malaria or anaemia 20 14.1 24 17.0 1.21 (0.66 to 2.23) 12 15.7 14 18.5 1.17 (0.54 to 2.53)
PCV=packed cell volume.
*Per 1000 child years at risk.
†Intracluster correlation log rank test 2=34.04; P<0.001.
‡Intracluster correlation log rank test 2=4.77; P=0.014.
§Intracluster correlation log rank test 2=0.03; P=0.435.
¶Intracluster correlation log rank test 2=1.26; P=0.131.
Table 2 Protective efficacy (95% confidence interval) and number of children protected per 1000 (95% confidence interval), by age group
Outcome
2-15 months 16-24 months 2-24 months
Protective efficacy (%)* No protected/1000 Protective efficacy (%)* No protected/1000 Protective efficacy (%)* No protected/1000
Malaria
All episodes of malaria 24.9 (14.5 to 34.1) 254.8 (183.0 to 326.6) −4.9 (−21.3 to 9.3) −53.0 (−146.0 to 39.9) 16.3 (6.7 to 25.0) 145.5
(88.7 to 202.4)
Malaria ≥5000/l 23.6 (11.1 to 34.3) 139.7 (83.6 to 195.9) −18.9 (−39.1 to −1.7) −98.1 (−171.5 to −24.7) 11.9 (0.5 to 22.0) 55.4 (10.8 to 100.0)
Hospital admissions
All causes 12.7 (−4.8 to 27.3) 37.5 (3.1 to 78.1) −0.4 (−31.3 to 23.3) 2.4 (−40.4 to 45.2) 9.5 (−7.5 to 23.8) 25.1 (5.3 to 55.4)
All malaria admissions 39.8 (14.0 to 57.9) 22.5 (6.2 to 38.7) 8.4 (−56.0 to 46.2) 3.6 (−17.5 to 24.7) 31.2 (5.4 to 49.9) 15.9 (3.0 to 28.8)
PCV<24% 35.5 (11.2 to 53.1) 23.9 (6.4 to 41.4) −9.0 (−81.3 to 34.4) −3.0 (−24.9 to 18.8) 24.2 (−0.5 to 42.8) 14.5 (0.8 to 28.2)
PCV<15% 44.4 (−20.6 to 74.3) 5.6 (1.7 to 12.9) 43.3 (−104.5 to 84.3) 3.9 (−4.7 to 12.4) 44.1 (−11.7 to 72.1) 5.0 (0.6 to 10.6)
Malaria + PCV<24% 53.3 (23.4 to 71.6) 18.3 (6.6 to 30.0) −28.4 (−195.1 to 44.1) −4.1 (−17.0 to 8.8) 38.8 (5.5 to 60.4) 10.5 (1.6 to 19.3)
Malaria + PCV<15% 36.3 (−94.9 to 79.2) 2.1 (−2.9 to 7.1) – 5.2 (0.1 to 10.4) 57.1 (−25.9 to 85.4) 3.2 (0.5 to 6.9)
Cerebral malaria 31.6 (−35.3 to 65.4) 4.2 (−4.1 to 12.5) 18.6 (−99.2 to 66.7) 5.1 (−8.5 to 18.8) 26.6 (−28.6 to 58.1) 4.5 (2.7 to 11.7)
Deaths
All causes −27.4 (−98.7 to 18.3) −6.4 (−18.7 to 5.9) −27.3 (−112.9 to 23.9) −9.5 (−29.4 to 10.3) −27.2 (−78.1 to 9.1) −7.5 (−18.1 to 3.1)
Malaria −21.4 (−123.2 to 34.0) −2.9 (−12.0 to 6.3) −17.0 (−153.1 to 45.9) −2.8 (−15.9 to 10.4) −19.1 (−92.0 to 25.1) −2.8 (−10.4 to 4.7)
PCV=packed cell volume.
*Adjusted for sex and rural/urban residence; protective efficacy (% reduction in outcomes in IPTi group)=(1−odds ratio)×100
Papers
730 BMJ VOLUME 331 1 OCTOBER 2005 bmj.com
A significant reduction in the incidence of hospital
admissions for malaria (37.8%, 11.8% to 56.1%)
occurred in the IPTi group up to 15 months of age.
IPTi had no significant effect on hospital admissions
for malaria between 16 and 24 months. From 2 to 24
months of age IPTi had a significant protective effect of
15.9% (3.0% to 28.8%) against hospital admissions for
malaria.
More deaths occurred in the IPTi group (77) than
in the placebo group (61), but this difference was not
statistically significant (table 1). The relative risk of
death up to 15 months of age in the IPTi group was
1.26 (0.81 to 1.96; P = 0.31), and from 16 to 24 months
it was 1.28 (0.77 to 2.14; P = 0.35). There were 32
deaths attributable to malaria in the placebo group and
38 deaths in the IPTi group. This difference was not
statistically significant.
Prevalence of anaemia and parasitaemia
Table B on bmj.com shows the prevalences of anaemia
and parasitaemia at approximately 3, 9, 12, and 18
months of age. The mean packed cell volume was sig-
nificantly higher in the IPTi group than in the control
group at 12 months of age, but it was slightly lower in
the IPTi group at 18 months. The prevalence of
malaria parasitaemia was lower in the IPTi group at 9,
12, and 18 months of age.
Effect of malaria transmission season on protective
efficacy of IPTi
Table 4 shows the protective efficacy of IPTi by number
of doses administered during wet and dry seasons in
2-12 month old infants. Children who received IPTi
doses 1 and 2 in the wet season and dose 3 in the dry
season had the maximum protective effect against
malaria (52%) and anaemia (72%). The next best
protective efficacy against malaria (37%) was obtained
by giving IPTi dose 2 during the wet season and doses
1 and 3 in the dry season. Although the effect was not
statistically significant, infants who received all three
IPTi doses in the dry season also seemed to have some
protection against malaria (24%).
Incidence of adverse events
The proportions of children who vomited after admin-
istration of drugs was similar between the two groups
(0.4% in the placebo group versus 0.3% in the
sulfadoxine-pyrimethamine group). Among the chil-
dren who were visited at home within four weeks after
administration of IPTi dose 1 (n = 1765, 74%) or dose
2 (n = 214, 9%), 32 (3.3%) children in the placebo
group and 27 (2.7%) in the sulfadoxine-
pyrimethamine group had skin rashes. None of the
skin rashes was severe or suggestive of a drug sensitiv-
ity reaction. The incidence of outpatient attendance for
any illness and hospital admissions due to any severe
illness during the month after IPTi doses 1, 2, 3, and 4
was lower in the IPTi group than in the placebo group
(table C on bmj.com). However, during the one month
period after IPTi dose 1, four deaths occurred in the
sulfadoxine-pyrimethamine group compared with
none in the placebo group. Similarly, during the month
after IPTi dose 2, six deaths occurred in the
sulfadoxine-pyrimethamine group compared with
none in the placebo group. Causes of these deaths
were as follows: malaria (4), diarrhoea disease (1), septi-
caemia (1), “spirit child” (probably herbal poisoning)
(2), and unknown (2). None of these deaths was consid-
ered to be associated with the IPTi drugs by the panel
of physicians who reviewed the verbal autopsy
questionnaires.
Discussion
Effect of malaria transmission intensity on IPTi
efficacy
The protective efficacy of intermittent preventive treat-
ment with sulfadoxine-pyrimethamine against malaria
and anaemia in infants observed in our study is
moderate and substantially lower than that reported
from Ifakara, Tanzania.8 This may be because of the
differences in the intensity and pattern of malaria
transmission between the two sites. The intensity of
transmission is low (entomological inoculation rate
31/year) and perennial in Ifakara,13 whereas it is very
high (418/year) and highly seasonal in Navrongo, our
study site.10 The incidence of malaria in the placebo
group was 0.43 episode/child/year in Ifakara com-
pared with 1.0 episode/child/year in Navrongo.
Although the protective efficacy of IPTi was higher in
Ifakara than in Navrongo, the number of episodes of
malaria prevented was similar at the two sites (260 v
255 per 1000 children per year) because the
background incidence of malaria was higher in
Navrongo. In spite of a higher incidence of malaria, the
Age (months)
Pr
op
or
tio
n
0 2 4 6 8 10 12 14 16 18 20 22 24
0
0.25
0.50
0.75
1.00
1.25
Average age at administration of doses
Sulfadoxine-pyrimethamine
Placebo
Kaplan-Meier survival estimates of time to first episode of malaria by
intervention group
Table 3 Protective efficacy against malaria during the first and second month after each dose of IPTi
IPTi dose
No
Malaria episodes during
first month after IPTi
Malaria episodes during
second month after IPTi
Protective efficacy (%)
during first month after
IPTi (95% CI)
Protective efficacy (%)
during second month
after IPTi (95% CI)
Placebo SP Placebo SP
Events PYAR Events PYAR Events PYAR Events PYAR
1 41 88.4 10 90.2 – – – – 77 (50 to 89) –
2 67 91.8 11 92.1 84 90.8 48 90.7 84 (69 to 91) 43 (19 to 60)
3 119 82.8 25 85.2 125 81.9 95 84.4 80 (68 to 87) 27 (4 to 44)
4 108 85.3 24 86.7 90 86.1 101 87.3 78 (65 to 86) −11 (−49 to 18)
IPTi=intermittent preventive treatment for malaria in infants; PYAR=person years at risk; SP=sulfadoxine-pyrimethamine.
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incidences of anaemia and hospital admissions in the
placebo group were lower in Navrongo than in Ifakara
(anaemia: 0.07 v 0.11/child/year; hospital admissions:
0.32 v 0.63/child/year). This difference may be due to
the fact that the Navrongo study covered a large area
(some children lived up to 40 km from the hospital)
whereas the study population of Ifakara lived within a
5 km radius of the hospital. The incidences of anaemia
and hospital admissions are probably underestimated
in both the placebo and IPTi groups in our study, and
thus the public health impact of IPTi on these
outcomes may also be underestimated;more cases may
have been prevented than we were able to detect.
Effect of malaria transmission season on IPTi
efficacy
IPTi dose 2 seemed to have a higher protective efficacy
against malaria than IPTi doses 1 and 3. Children who
received their IPTi dose 2 in the wet season had 46%
protection against malaria between 2 and 12 months
of age, whereas those who received this dose in the dry
season had only 16% protection. Similarly, children
who received dose 1 in the wet season had 42% protec-
tion compared with 19% protection in those who
received dose 1 in the dry season. Children who
received dose 3 in the wet season had only 15%
protection compared with 38% protection in those
who had dose 3 in the dry season. This is because chil-
dren who received dose 3 in the dry season had
received dose 1, dose 2, or both in the wet season. Chil-
dren who received IPTi doses 1 and 2 in the wet season
and dose 3 in the dry season had the maximum
protection against malaria (52%), which is comparable
to the protective efficacy of IPTi observed in Ifakara
(62%). It seems that offering IPTi with sulfadoxine-
pyrimethamine at the time of DPT-2 and DPT-3 during
the wet season alone would have the maximum benefit,
although giving IPTi year round may be beneficial in
this area with high seasonal transmission. However, as
this study was not designed to detect the efficacy of dif-
ferent dosing schedules, these data need to be
interpreted with caution. In Senegal, Cisse et al
observed 86% protection against clinical attacks of
malaria by administering three doses of sulfadoxine-
pyrimethamine plus artesunate to children under 5
years old on three occasions during the malaria trans-
mission season,14 and similar results have been
obtained in Mali.15 Further studies of appropriate dos-
ing schedules for IPTi in high, seasonal transmission
areas are needed.
Mode of action of IPTi
Protection against malaria during the one month
period after an IPTi dose is much higher than the
overall effect of IPTi from 2 to 15 months of age. This
suggests that IPTi using sulfadoxine-pyrimethamine
reduces the incidence of malaria and anaemia, at least
in part, through its chemoprophylactic effect, which is
known to last for about a month. However, the fact that
doses 1 and 2 administered during the high transmis-
sion season had a higher protective efficacy than dose
3 suggests that reducing the number of infections
between 3 and 6 months of age may modulate the
immune response and thereby give greater protection
for prolonged periods. This hypothesis needs to be
tested by using long acting and short acting antimalar-
ials and studying their effect on immune responses.
Rebound effect of IPTi
The IPTi study from Tanzania did not find a rebound
increase in the incidence of malaria when IPTi was
stopped and even found some evidence of persistence
of protection into the second year of life.16 However, we
found a significant increase in malaria attacks
associated with high density parasitaemia and a slight
decrease in mean packed cell volume between 16 and
24 months of age when the effect of IPTi had worn off.
This could be due to the differences in the level of
intensity of transmission. Our finding of a potential
rebound effect suggests that a careful monitoring of
rebound effect is needed if IPTi is implemented on a
large scale. Sulfadoxine-pyrimethamine IPTi did not
increase the incidence of common adverse events such
as vomiting and skin rash, and the incidence of any ill-
ness that needed medical attention was lower in the
IPTi group than in the placebo group. However, 10
deaths occurred during the first month after IPTi
whereas none occurred in the placebo group in this
period. Although none of the deaths was deemed to be
caused by IPTi, this trend needs to be carefully
monitored in all IPTi studies and implementation
programmes.
Effect of insecticide treated nets plus IPTi
Insecticide treated bed nets reduce the incidence of
malaria and anaemia substantially. A meta-analysis
showed that nets reduce episodes of malaria by 50%
(95% confidence interval 45% to 55%) and increase
mean packed cell volume by 1.7% in children aged
under 5 years.17 A combination of nets plus malaria
chemoprophylaxis (pyrimethamine-dapsone) reduced
the incidence of malaria by 97% (92% to 99%) and
increased the mean packed cell volume by 1.2%
Table 4 Protective efficacy of IPTi by season of administration in 2-12 month old infants. Values are percentages (95% confidence
intervals)
Doses administered
No of
children
All episodes
of malaria*
Malaria episodes with
parasite ≥5000/l*
Anaemia
(PCV<24)
Hospital admissions
for malaria
1, 2, and 3 in dry season 524 24 (−7 to 46) 31 (−6 to 55) 44 (−122 to 86) 61 (−91 to 7)
1 in wet, 2 and 3 in dry 363 2 (−54 to 37) −13 (−103 to 38) 67 (−216 to 97) –
2 in wet, 1 and 3 in dry 366 37 (10 to 56) 24 (−22 to 52) 17 (−232 to 79) −105 (−958 to 60)
3 in wet, 1 and 2 in dry 1901 15 (−1 to 28) 17 (−2 to 33) 29 (−31 to 62) 43 (−5 to 69)
1 and 2 in wet, 3 in dry 965 52 (37 to 63) 57 (38 to 70) 72 (12 to 91) 57 (−135 to 92)
1 and 3, 2 and 3, or all three in wet 112 28 (−40 to 63) 24 (−73 to 67) 28 (−1046 to 4) –
1, 2, and 3 in any season 2098 27 (16 to 37) 28 (14 to 39) 43 (11 to 64) 44 (8 to 66)
PCV=packed cell volume.
*Up to 28 days person time at risk and any episodes excluded after treatment with chloroquine or other antimalarial agent.
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compared with nets alone.18 Only 17% of the placebo
group and 19% of the IPTi group in our study popula-
tion had used any form of net. Among the children
who used a net, addition of IPTi gave 19% ( − 2% to
35%; P = 0.07) protection against malaria compared
with children who received the placebo. Those using a
net had no rebound effect of high parasite density
malaria between 16 and 24 months of age (protective
efficacy 4%, − 47% to 38%; P = 0.83). These results
should be interpreted with caution, however, as this
study was not designed to evaluate the combined effect
of nets plus IPTi. Distribution of nets is increasingly
linked with immunisation, and the coverage of nets in
children attending immunisation clinics has increased
remarkably from 4% to 94% in a district in Ghana.19 If
this approach to the delivery of nets continues, both
nets and IPTi will reach the same population, so
assessing the combined effect of nets and IPTi on
malaria is important, particularly the possible rebound
effect in the second year of life. Any potential rebound
effect might be offset by the continued protection
offered by nets. On the other hand, the net plus IPTi
combination might give almost total protection against
malaria infection during infancy and impair naturally
acquired immunity, as seen with continuous chemo-
prophylaxis,7 and increase the burden of severe
malaria later in life.20
Conclusions
More data are needed to decide on the appropriate
dose schedule for IPTi in areas with high seasonal
transmission and its interaction with insecticide treated
bed nets. However, intermittent preventive treatment
in infants with sulfadoxine-pyrimethamine linked to
the expanded programme of immunisation schedule
has the potential to reduce the burden of malaria even
in areas with high, seasonal transmission.
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What is already known on this topic
Intermittent preventive treatment for malaria in
infants with sulfadoxine-pyrimethamine
substantially reduced the incidence of malaria and
anaemia in Tanzania
This was in an area of low, perennial transmission
of malaria
What this study adds
Four courses of sulfadoxine-pyrimethamine given
at DPT-2, DPT-3, and measles vaccination and at
12 months of age reduced malaria (25%) and
anaemia (35%) up to age 15 months in a high,
seasonal transmission area in Ghana
The incidence of high parasite density malaria
increased 20% when treatment was stopped
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